This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 01, 2012 9:00 am ET
F. Michael Ball - Chief Executive Officer, Director and Member of Science, Technology & Quality Committee
Thomas E. Werner - Chief Financial Officer and Senior Vice President of Finance
Sumant Ramachandra - Chief Scientific Officer and Senior Vice President of R&D, Medical & Regulatory
David H. Roman - Goldman Sachs Group Inc., Research Division
Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division
John M. Putnam - Capstone Investments, Research Division
Ami Fadia - UBS Investment Bank, Research Division
Matthew Taylor - Barclays Capital, Research Division
Marshall Urist - Morgan Stanley, Research Division
Gregory B. Gilbert - BofA Merrill Lynch, Research Division
Shibani Malhotra - RBC Capital Markets, LLC, Research Division
Welcome to Hospira's Second Quarter 2012 Conference Call. [Operator Instructions] I will now turn the call over to Karen King, Vice President of Investor Relations. Karen, you may now begin your conference.
Thank you. Good morning, everyone, and welcome to our second quarter 2012 conference call and webcast. Participating in today's call are Mike Ball, Chief Executive Officer, Hospira; Tom Werner, Senior Vice President, Finance and Chief Financial Officer; and Sumant Ramachandra, Senior Vice President and Chief Scientific Officer.
We will be making some forward-looking statements today, which are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those indicated. A discussion of these factors is included in the Risk Factors and MD&A sections in Hospira's latest annual report on Form 10-K and subsequent Form 10-Qs on file with the SEC. We undertake no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.